SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

2/9/23 12:31:05 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RPRX alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 ROYALTY PHARMA PLC CLASS A COMMON STOCK Cusip #G7709Q104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #G7709Q104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 43,807,455 Item 6: 0 Item 7: 44,110,365 Item 8: 0 Item 9: 44,110,365 Item 11: 9.999% Item 12: HC Cusip #G7709Q104 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 44,110,365 Item 8: 0 Item 9: 44,110,365 Item 11: 9.999% Item 12: IN Item 1(a). Name of Issuer: ROYALTY PHARMA PLC Item 1(b). Address of Issuer's Principal Executive Offices: 110 East 59th Street New York, NY 10022 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: CLASS A COMMON STOCK Item 2(e). CUSIP Number: G7709Q104 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 44,110,365 (b) Percent of Class: 9.999% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 44,110,365 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of ROYALTY PHARMA PLC. No one other person's interest in the CLASS A COMMON STOCK of ROYALTY PHARMA PLC is more than five percent of the total outstanding CLASS A COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 9, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Diversifying Solutions LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 9, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the CLASS A COMMON STOCK of ROYALTY PHARMA PLC at December 30, 2022. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January, 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $RPRX alert in real time by email

Recent Analyst Ratings for

$RPRX

Date	Price Target	Rating	Analyst
1/30/2026	$49.00	Neutral → Buy	UBS
9/30/2025	$42.00	Buy	Goldman
5/16/2025	$51.00	Overweight	Morgan Stanley
6/3/2024	$28.00	Buy → Neutral	UBS
6/14/2022	$47.00	Buy	UBS
5/13/2022	$53.00	Sector Outperform	Scotiabank
4/27/2022	$56.00	Buy	Goldman
4/14/2022	$50.00	Neutral → Overweight	JP Morgan

More analyst ratings

SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

2/9/23 12:31:05 PM ET

$RPRX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RPRX alert in real time by email

Recent Analyst Ratings for

$RPRX

Date	Price Target	Rating	Analyst
1/30/2026	$49.00	Neutral → Buy	UBS
9/30/2025	$42.00	Buy	Goldman
5/16/2025	$51.00	Overweight	Morgan Stanley
6/3/2024	$28.00	Buy → Neutral	UBS
6/14/2022	$47.00	Buy	UBS
5/13/2022	$53.00	Sector Outperform	Scotiabank
4/27/2022	$56.00	Buy	Goldman
4/14/2022	$50.00	Neutral → Overweight	JP Morgan

More analyst ratings

SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$RPRX

SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$RPRX

$RPRX
Press Releases

Royalty Pharma to present at upcoming investor conferences

Royalty Pharma reports first quarter 2026 results

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

$RPRX
Analyst Ratings

Royalty Pharma upgraded by UBS with a new price target

Goldman initiated coverage on Royalty Pharma with a new price target

Morgan Stanley initiated coverage on Royalty Pharma with a new price target

$RPRX
Insider Trading

EVP & CFO Coyne Terrance P. sold $3,476,116 worth of Class A Ordinary Shares (64,399 units at $53.98) as part of a pre-agreed trading plan (SEC Form 4)

EVP, Research & Investments Urist Marshall sold $721,838 worth of Class A Ordinary Shares (13,684 units at $52.75) as part of a pre-agreed trading plan, decreasing direct ownership by 43% to 18,197 units (SEC Form 4)

Director Norden Gregory sold $161,385 worth of Class A Ordinary Shares (3,045 units at $53.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 191,803 units (SEC Form 4)

$RPRX
SEC Filings

Royalty Pharma plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

SEC Form 144 filed by Royalty Pharma plc

SEC Form 13F-NT filed by Royalty Pharma plc

$RPRX
Leadership Updates

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

Royalty Pharma Announces Expansion of Leadership Team

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

$RPRX
Financials

Royalty Pharma reports first quarter 2026 results

Royalty Pharma Declares Second Quarter 2026 Dividend

Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026

$RPRX
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Royalty Pharma plc

Amendment: SEC Form SC 13D/A filed by Royalty Pharma plc